Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3844583 in Healthy Participants and Patients With Atopic Dermatitis
NCT05486208Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY3844583 in atopic dermatitis (AD) (12 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Adverse Events at 183 days. Started Aug 2022; status: terminated.
02
Drugs
LY3844583
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05486208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486208.